13D Filing: Culpepper Peter R and Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT)

This Amendment No. 3 to a Statement on Schedule 13D
(this Statement) relates to common stock, par value $0.001 per share (Common Stock), of Provectus Biopharmaceuticals, Inc. (the Issuer). The address of the principal executive office of the Issuer is: 7327 Oak
Ridge Highway, Suite A, Knoxville, Tennessee 37931. This is the final amendment to this Statement and constitutes an exit filing for the Reporting Person.

Item 4 of this Statement is amended so that, as amended,
it states the following:

Culpepper has become a member of a group, for purposes of Rule 13d-3 of the Securities Exchange Act
of 1934, as amended (the Group), which filed a Schedule 13D with the Securities and Exchange Commission on March 30, 2017. Going forward, information about Culpepper will be included in filings made on behalf of the Group. This
Statement constitutes an exit filing because Culpepper is not required to make individual filings.